FDA Grants Fast Track Designation to Alpharadin for the Treatment of Castration-Resistant Prostate Cancer Patients ...
Not intended for U.S. MediaOslo, Norway, 23 August 2011 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, today announced that Alpharadin (radium-223 chloride) has been granted Fast Track